| Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House |
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics. |
accessnewswire.com |
2025-04-28 13:45:00 |
Czytaj oryginał (ang.) |
| Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript |
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions]. |
seekingalpha.com |
2025-03-11 22:07:06 |
Czytaj oryginał (ang.) |
| Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million |
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2025, ended January 31, 2025. Third Quarter and Recent Highlights: Total revenue increased 42% to $17.0 million Gross profit of $10.4 million; gross margin of 61% Net income of approximately $4.5 million Adjusted EBITDA of $5.2 million Signed first data licensing deal worth up to $8.0 million Hired Matt Newman, Executive Vice President and General Manager, to lead and expand the development of Champions' data licensing platform Year to Date Highlights: Total revenue increased 23% to $44.6 million Gross profit of $23.5 million; gross margin of 53% Net income of $6.5 million Adjusted EBITDA of $8.3 million Ronnie Morris, CEO of Champions, commented, "Our third quarter was transformational, marked by our first major data licensing agreement-an important milestone toward monetizing our proprietary data platform. |
accessnewswire.com |
2025-03-11 17:55:00 |
Czytaj oryginał (ang.) |
| Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025 |
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2025, on Tuesday, March 11, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. |
accessnewswire.com |
2025-03-06 18:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting |
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes. |
accessnewswire.com |
2025-02-18 11:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership |
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. |
accesswire.com |
2025-01-08 10:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies |
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion. |
seekingalpha.com |
2024-12-27 11:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript |
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call. |
seekingalpha.com |
2024-12-11 20:02:25 |
Czytaj oryginał (ang.) |
| Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million |
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024. Second Quarter and Recent Highlights: Total revenue increased 17% to $13.5 million Gross profit of $6.1 million; margin of 45% Net income of approximately $730,000 Adjusted EBITDA of $1.1 million Development of new data revenue stream First Half 2025 Highlights: Total revenue increased 14% to $27.6 million Gross profit of $13.1 million; margin of 47% Net income of $2.1 million Adjusted EBITDA of $3.2 million Ronnie Morris, CEO of Champions, commented, "Our second quarter's performance solidified our confidence in the Company's turnaround that we've been discussing the last several quarters. |
accesswire.com |
2024-12-11 18:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024 |
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. |
accesswire.com |
2024-12-05 18:30:00 |
Czytaj oryginał (ang.) |
| Champions Oncology Announces Agreement with Weill Cornell Medicine |
HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing (CTL), part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft (PDX) models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center. |
accesswire.com |
2024-10-16 14:55:00 |
Czytaj oryginał (ang.) |
| Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript |
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2025 Earnings Conference Call September 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call. |
seekingalpha.com |
2024-09-12 00:52:07 |
Czytaj oryginał (ang.) |
| Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million |
HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024. First Quarter Highlights: Total revenue increased 12% to $14.1 million Margin improved to 50% Adjusted EBITDA of $2.0 million Net income of $1.3 million Ronnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. |
accesswire.com |
2024-09-11 20:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024 |
HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. |
accesswire.com |
2024-09-09 20:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology Reports Quarterly Revenue of $14.0 Million |
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024. Fourth Quarter Financial Highlights: Fourth quarter revenue increased 7% to $14 million Adjusted EBITDA fourth quarter income of $884,000 Fourth quarter gross margin on pharmacology services of 49% Fiscal Year 2024 Financial Highlights: Annual revenue of $50.2 million, a decrease of 7% year-over-year Fiscal Year 2024 adjusted EBITDA loss of $3.9 million Fiscal Year 2024 gross margin on pharmacology services of 42% Ronnie Morris, CEO of Champions, commented, "As we discussed over the year, we'd be facing hurdles during fiscal 2024 due to the challenging funding environment in the biotech sector and a range of spending patterns from our larger pharmaceutical companies, leading to a slowdown in sales growth and an increase in cancellations. |
accesswire.com |
2024-07-18 20:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024 |
HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. |
accesswire.com |
2024-07-11 20:05:00 |
Czytaj oryginał (ang.) |
| Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development |
HACKENSACK, NJ / ACCESSWIRE / June 4, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, has announced a strategic partnership with Medicines Discovery Catapult (MDC), enhancing their combined capabilities in the expanding field of radiopharmaceutical therapeutics. This collaboration combines Champions Oncology's robust portfolio of patient-derived models and pharmacology solutions with MDC's expertise in radio-conjugates, radiochemistry, and advanced multi-modal functional imaging. |
accesswire.com |
2024-06-04 13:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript |
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-03-12 21:21:03 |
Czytaj oryginał (ang.) |
| Champions Oncology Reports Quarterly Revenue of $12.0 Million |
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024. Third Quarter and Recent Highlights: Third quarter revenue of $12.0 million, a decline of 6% Gross margin declined to 35% College of American Pathologists (CAP) has awarded accreditation to US-based laboratory Ronnie Morris, CEO of Champions, commented, "As discussed over the course of the year, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approximately one year ago. |
accesswire.com |
2024-03-12 18:30:00 |
Czytaj oryginał (ang.) |
| Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation |
HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced that the College of American Pathologists (CAP) has awarded accreditation to its US-based laboratory. This achievement of CAP accreditation continues to strengthen Champions Oncology's reputation as a high-quality, state of the art laboratory providing the highest standards of excellence in histology and immunohistochemistry services. |
accesswire.com |
2024-03-07 11:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024 |
HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. |
accesswire.com |
2024-03-06 18:35:00 |
Czytaj oryginał (ang.) |
| Champions Oncology, Inc. (CSBR) Q2 2024 Earnings Call Transcript |
Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2024 Earnings Conference Call December 12, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call. |
seekingalpha.com |
2023-12-12 19:54:09 |
Czytaj oryginał (ang.) |
| Champions Oncology Reports Quarterly Revenue of $11.6 Million |
HACKENSACK, NJ / ACCESSWIRE / December 12, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2024, ended October 31, 2023. Second Quarter and Recent Highlights: Second quarter revenue of $11.6 million, a decline of 19% Revised fiscal year 2024 revenue guidance to be generally in-line with last year's results Strong quarterly bookings European lab received ISO accreditation and ATS certification Hired Brady Davis as President to develop new strategic initiatives Ronnie Morris, CEO of Champions, commented, "As discussed during our first quarter earnings call, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approximately one year ago. |
accesswire.com |
2023-12-12 18:00:00 |
Czytaj oryginał (ang.) |
| Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023 |
HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. |
accesswire.com |
2023-12-04 18:30:00 |
Czytaj oryginał (ang.) |
| Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification |
HACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its European research operations site in Bresso, Italy, received ISO-9001:2015 laboratory accreditation from the Bureau Veritas S.p.A. and ATS certification from the Lombardy Region. |
accesswire.com |
2023-11-02 10:30:00 |
Czytaj oryginał (ang.) |
| Champions Oncology Announces the Addition of Brady Davis as President |
HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth. "We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. |
accesswire.com |
2023-10-17 12:30:00 |
Czytaj oryginał (ang.) |